Golimumab

戈利木单抗

Report date: 2024/08/05 10:27:35

Base Information

Drug NameGolimumab
Drug Alias NameAnti-TNF-alpha monoclonal antibody戈里木单抗GolimumabumSimponi I.VSimponi aria +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPediatric ulcerative colitisNon-radiographic axial spondyloarthritisAxial Spondyloarthritis +[12] 
Global Approved IndicationsColitis, UlcerativeArthritis, RheumatoidSpondylitis, Ankylosing +[4] 
Approved Indications in ChinaArthritis, RheumatoidSpondylitis, Ankylosing
Original Approved Country/TerritoryUnited States
Original Approved Date2009/04/24
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineJohnson & Johnson (China) Investment LtdGhent University +[8] 
Inactive CompaniesJanssen Services LlcSchering-PloughHouse Ear Institute +[7] 
Active IndicationsPediatric ulcerative colitisAxial SpondyloarthritisDiabetes Mellitus, Type 1 +[8] 
Inactive IndicationsNon-radiographic axial spondyloarthritisLabyrinth DiseasesAsthma +[4] 

Other Information

ATC CodeL04AB06
Related LinksWikipediaDrugBankKEGG